• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma

byConstance WuandAliya Ramjaun
November 5, 2018
in Chronic Disease, Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Programmed death-1 (PD-1) inhibitors have shown efficacy in the treatment of melanoma. Pre-existing CD8+ T-cell infiltrate and interferon (IFN) gene signature has been shown to correlate with response to PD-1 blockade. As such, the receipt of combination therapy with interferon (IFN) may enhance anti-tumor effects. In this open-label phase Ib/II trial, investigators treated 43 patients with stage IV PD-1-naïve melanoma with escalating doses of pegylated (PEG)-IFN combined with pembrolizumab (2mg/kg every 3 weeks, intravenously) until disease progression, in order to study the safety and objective response rate of the combination therapy. The phase II portion of the study examined the recommended phase II dose, and included a subset of 31 patients. Researchers found that no dose-limiting toxicity was found for any of the three PEG-IFN dose cohorts (1 µg/kg, 2 µg/kg, and 3 µg/kg). As such, 3 µg/kg of PEG-IFN was combined with 2 mg/kg of pembrolizumab for the phase II portion of the trial. Two patients with the highest PEG-IFN dose experienced grade 4 events and discontinued treatment, but still showed ongoing responses. In terms of efficacy, investigators assessed the objective response rate to be 60.5%, with 46.5% of patients exhibiting an ongoing response. Median time to response was 12 weeks, and median progression-free survival was 11 months (95% CI 6 months to not reached) in all patients. Progression-free survival rates at 6, 12, and 24 months were 64%, 46%, and 46%, respectively, in all patients. In non-responders, progression-free survival was 6 months (95% CI 2 months to 8 months). Results from this trial therefore suggest that the combination of pembrolizumab and PEG-IFN exhibits important clinical activity for PD-1 naïve melanoma, as the objective response rate of 60.5% was higher than the current disease control rate of 48.8%. It is important to note, however, that this study did not have a control group, and that this study had findings in contrast to another phase IB study testing pembrolizumab and PEG-IFN I melanoma. As such, further studies are needed to evaluate the safety and efficacy of this combination treatment.

Click to read this study in JCO

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

Tags: melanoma
Previous Post

E-cigarette users have greater odds of subsequent cigarette use

Next Post

Quick Take: Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia

RelatedReports

Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025
“No Evidence of Disease Activity” may be useful goal in multiple sclerosis
Chronic Disease

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

February 24, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
Medicare beneficiaries have a lower rate of delayed melanoma surgeries
Chronic Disease

Adjuvant dabrafenib and trametinib improve survival in stage III melanoma

November 25, 2024
Next Post
Combined MRI and NIH stroke scores may predict stroke prognosis

Quick Take: Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia

WIC revisions associated with higher diet quality in children

Organic food consumption linked to reduced cancer risk

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

Quick Take: Association of Weather With Day-to-Day Incidence of Myocardial Infarction: A SWEDEHEART Nationwide Observational Study

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.